Anixa Biosciences (ANIX) FCF Margin (2010 - 2023)

Anixa Biosciences' (ANIX) quarterly FCF Margin came in at 384.29% in Q2 2023, down 100.37% on a QoQ basis from 104500.0% in Q4 2021.

Anixa Biosciences (ANIX) FCF Margin (2010 - 2023) Analysis & Trends

Anixa Biosciences (ANIX) has 11 years of FCF Margin data on file, last reported at 384.29% in Q2 2023.

Quarterly FCF Margin changed N/A year-over-year to 384.29% in Q2 2023, while the trailing twelve-month figure through Oct 2023 was 2970.81% (changed N/A YoY) and the FY2023 annual result came in at 2956.67%, changed N/A from the prior year.
FCF Margin slipped to 384.29% in Q2 2023, from 104500.0% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 104500.0% in Q4 2021 to a low of 573.9% in Q2 2019.
A 3-year average of 25828.44% and a median of 306.18% in 2023 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 47366 bps in 2019, down 47366 bps in 2019.
Tracing ANIX's FCF Margin over 3 years: stood at 573.9% in 2019, then surged by 18309 bps to 104500.0% in 2021, then slumped by 100 bps to 384.29% in 2023.
The last three FCF Margin figures came in at 384.29% (Q2 2023), 104500.0% (Q4 2021), and 228.07% (Q1 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	13.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	41.07%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	Anixa Biosciences	123.62 Mn	123.62 Mn	-	-

Download Data